A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human Interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 100–300 CD4 + t cells
| Autor: | de Boer, Alberdina W, Markowitz, Norman, Lane, H.Clifford, Saravolatz, Louis D, Koletar, Susan L, Donabedian, Haig, Yoshizawa, Carl, Duliege, Anne-Marie, Fyfe, Gwendolyn, Mitsuyasu, Ronald T |
|---|---|
| Zdroj: | In Clinical Immunology 2003 106(3):188-196 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect